Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1374342 | Bioorganic & Medicinal Chemistry Letters | 2011 | 5 Pages |
Abstract
A computation docking study of the highly potent, non-nitrogen containing, acetylcholinesterase inhibitor (+)-arisugacin A is presented. The model suggests that (+)-arisugacin A is a dual binding site covalent inhibitor of AChE. These findings are examined in the context of Alzheimer’s disease-modifying therapeutic design. (+)-Arisugacin A’s revealed mode of action is unique, and may serve as a basis for the development of AD therapeutics capable of treating the symptomatic aspects of AD, while being neuroprotective with long term efficacy.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Ziyad F. Al-Rashid, Richard P. Hsung,